Stellar Biotechnologies Inc (SBOT)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Stellar Biotechnologies Inc (SBOT) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011361
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月22日
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Stellar Biotechnologies Inc (Stellar Bio), formerly CAG Capital Inc is a provider of keyhole limpet hemocyanin proteins. The company offers potent immune-stimulating molecule used as an active pharmaceutical ingredient known as active immunotherapies or therapeutic vaccines and as an injectable product to assess immune response. Its products comprise Stellar KLH protein which can be used in various grades, formulations, and configurations for both clinical and research applications and KLH Elisa Kits. Stellar Bio’s products are used in immunotherapies as an immune stimulant in immunotoxicology applications and therapeutic vaccine conjugation. The company partners with research centers and developers of active immunotherapies and therapeutic vaccines. Stellar Bio is headquartered in Port Hueneme, California, the US.

Stellar Biotechnologies Inc (SBOT) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Stellar Biotechnologies Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Stellar Biotechnologies Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Stellar Biotechnologies Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Stellar Biotechnologies Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
Stellar Biotechnologies Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Stellar Biotechnologies Inc, Medical Equipment, Deal Details 10
Equity Offering 10
Stellar Biotechnologies Completes Second Tranche Private Placement Of Units For US$12 Million 10
Stellar Biotechnologies Completes Second Tranche Of Private Placement Of Units For US$5 Million 12
Stellar Biotechnologies Completes Private Placement Of Units For US$1.6 Million 14
Stellar Biotechnologies Inc – Key Competitors 15
Stellar Biotechnologies Inc – Key Employees 16
Stellar Biotechnologies Inc – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Joint Venture 17
Recent Developments 18
Financial Announcements 18
Dec 01, 2017: Stellar Biotechnologies Reports Fiscal Year 2017 Financial Results 18
May 09, 2017: Stellar Biotechnologies Reports Second Quarter 2017 Financial Results 19
Feb 06, 2017: Stellar Biotechnologies Reports First Quarter 2017 Financial Results 21
Dec 14, 2016: Stellar Biotechnologies Reports Fiscal Year 2016 Financial Results 22
Aug 09, 2016: Stellar Biotechnologies Reports Third Quarter 2016 Financial Results and Operational Highlights 23
May 09, 2016: Stellar Biotechnologies Reports Second Quarter 2016 Financial Results and Operational Highlights 25
Feb 08, 2016: Stellar Biotechnologies Reports First Quarter 2016 Financial Results and Operational Highlights 26
Corporate Communications 27
Jun 07, 2017: Stellar Biotechnologies Expands Operations Team 27
Dec 09, 2016: Stellar Biotechnologies appoints two new board members 28
Dec 09, 2016: Stellar Biotechnologies Appoints Pharma and Capital Markets Experts to Board of Directors 29
Oct 24, 2016: Stellar Board Member and Pharma Expert to Join Executive Team 30
Oct 05, 2016: Stellar Appoints Investor Relations Executive to Management Team to Support Its Continuing Scale-Up 31
Jul 19, 2016: Neovacs and Stellar Biotechnologies Announce changes of Administrative Board and Management Team 32
May 23, 2016: Stellar Biotechnologies Appoints Michael L. Klein, Ph.D. as Vice President of Chemistry, Manufacturing and Controls 33
Legal and Regulatory 34
Mar 29, 2016: Stellar Biotechnologies’ Announces Effective Date of TSX-V Voluntary Delisting 34
Mar 23, 2016: Stellar Biotechnologies Applies for Voluntary Delisting From TSX Venture Exchange 35
Government and Public Interest 36
Jan 26, 2016: Stellar Biotechnologies Presents Research on Nanofiltration Development at PepTalk Conference 36
Other Significant Developments 37
Mar 06, 2017: The Life Sciences Report Examines Stellar Biotechnologies Inking Multiyear KLH Supply Agreement with Amaran Biotechnology; Stellar Up 27% on News 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Stellar Biotechnologies Inc, Medical Equipment, Key Facts, 2016 2
Stellar Biotechnologies Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Stellar Biotechnologies Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Stellar Biotechnologies Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Stellar Biotechnologies Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Stellar Biotechnologies Inc, Deals By Market, 2011 to YTD 2017 8
Stellar Biotechnologies Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Stellar Biotechnologies Completes Second Tranche Private Placement Of Units For US$12 Million 10
Stellar Biotechnologies Completes Second Tranche Of Private Placement Of Units For US$5 Million 12
Stellar Biotechnologies Completes Private Placement Of Units For US$1.6 Million 14
Stellar Biotechnologies Inc, Key Competitors 15
Stellar Biotechnologies Inc, Key Employees 16
Stellar Biotechnologies Inc, Joint Venture 17

★海外企業調査レポート[Stellar Biotechnologies Inc (SBOT)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kumho Petrochemical Co Ltd (011780):企業の財務・戦略的SWOT分析
    Kumho Petrochemical Co Ltd (011780) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Charles River Laboratories International Inc (CRL)-医療機器分野:企業M&A・提携分析
    Summary Charles River Laboratories International Inc (Charles River) is a contract research organization (CRO) that provides essential products and services to accelerate the research, drug discovery and development. It offers various basic research, drug discovery and safety assessment services. Th …
  • Universal Music Group Inc:企業の戦略的SWOT分析
    Universal Music Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • bluebird bio Inc (BLUE):企業の財務・戦略的SWOT分析
    bluebird bio Inc (BLUE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Navistar International Corporation:企業のM&A・事業提携・投資動向
    Navistar International Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Navistar International Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on m …
  • Xylem Inc (XYL):電力:M&Aディール及び事業提携情報
    Summary Xylem Inc (Xylem) is a water technology company. It designs, manufactures, and services engineered solutions ranging across a wide variety of applications. The company’s offerings address customer needs across the water cycle, from the delivery, measurement and use of drinking water to the c …
  • Symbiomix Therapeutics LLC-製薬・医療分野:企業M&A・提携分析
    Summary Symbiomix Therapeutics LLC (Symbiomix) is a drug development company that offers development and commercialization of novel medicines. The company offers SYM-1219, for the treatment of several serious infections in women including bacterial vaginosis. Its SYM-1219 contains secnidazole, nitro …
  • Li Ning Company Ltd (2331)
    Li Ning Company Ltd (2331) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Aurora Health Care Inc:企業の戦略的SWOT分析
    Aurora Health Care Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Canadian Spirit Resources Inc (SPI):石油・ガス:M&Aディール及び事業提携情報
    Summary Canadian Spirit Resources Inc (CSRI) is a natural resource provider that provides exploration and development services. The company offers exploration and production of natural gas in Montney Formation of Northeast British Columbia. It provides operation Farrell Creek area which is located a …
  • Alfresa Holdings Corp (2784):製薬・医療:M&Aディール及び事業提携情報
    Summary Alfresa Holdings Corp (Alfresa) is a manufacturer and marketer of pharmaceuticals, diagnostic reagent and medical devices. The company offers ethical pharmaceuticals wholesaling, self-medication products and manufacturing. It’s ethical pharmaceutical wholesaling business supplies diagnostic …
  • University of Texas Southwestern Medical Center-製薬・医療分野:企業M&A・提携分析
    Summary University of Texas Southwestern Medical Center (UTSMC), a subsidiary of University of Texas System is an educational center that offers medical research and education programs. The center offers degree programs, which include master's degree in business administration, public health, medica …
  • Lakeland Bancorp, Inc.:企業の戦略・SWOT・財務情報
    Lakeland Bancorp, Inc. - Strategy, SWOT and Corporate Finance Report Summary Lakeland Bancorp, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Bank of Cyprus Public Company Ltd:企業のM&A・事業提携・投資動向
    Bank of Cyprus Public Company Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bank of Cyprus Public Company Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • CRELUX GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Crelux GmbH (Crelux), a subsidiary of WuXi AppTec (Shanghai) Co Ltd, is a drug discovery company that discovers drug solutions for pharmacy, biotech and research organizations. The company offers customized and integrated services in areas of drug discovery, X-ray crystallography, protein su …
  • WGL Holdings Inc (WGL):企業の財務・戦略的SWOT分析
    WGL Holdings Inc (WGL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Paychex, Inc. (PAYX):企業の財務・戦略的SWOT分析
    Paychex, Inc. (PAYX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Fanhua Inc:企業のM&A・事業提携・投資動向
    Fanhua Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Fanhua Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Regenicin Inc (RGIN):医療機器:M&Aディール及び事業提携情報
    Summary Regenicin Inc (Regenicin), formerly Windstar Inc is a biotechnology company that develops regenerative cell therapies. The company offers NovaDerm, a tissue-engineered skin prepared from autologous skin cells. Its NovaDerm technology uses the patient’s own skin cells to generate living, tiss …
  • Cerenis Therapeutics Holding SA (CEREN):企業の財務・戦略的SWOT分析
    Summary Cerenis Therapeutics Holding SA (Cerenis) is a biopharmaceutical company that discovers and develops HDL therapies for the treatment of cardiovascular and metabolic diseases. The company develops a portfolio of HDL therapies including HDL mimetics for the rapid regression of atherosclerotic …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆